DOCSLIB.ORG

RNA Interference, Understanding the Collateral Effects of HIV-1 and ZIKV

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RNA Interference, Understanding the Collateral Effects of HIV-1 and ZIKV RNA interference, understanding the collateral effects of HIV-1 and ZIKV Sergio Paulo Alpuche Lazcano Department of Medicine Division of Experimental Medicine McGill University, Montréal, Québec, Canada December, 2019 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy. © Sergio Paulo Alpuche Lazcano, 2019 Table of Contents LIST OF FIGURES ........................................................................................................................ 7 LIST OF TABLES .......................................................................................................................... 8 ABSTRACT .................................................................................................................................. 10 RÉSUMÉ ...................................................................................................................................... 12 ACKNOWLEDGMENTS ............................................................................................................ 14 LIST OF ABBREVIATIONS ....................................................................................................... 16 CONTRIBUTION TO ORIGINAL KNOWLEDGE ................................................................... 24 CONTRIBUTION OF AUTHORS............................................................................................... 25 CHAPTER I .................................................................................................................................. 27 INTRODUCTION ................................................................................................................... 27 1.1 RNA interference (RNAi) ................................................................................................... 28 1.1.1 RNAi discovery and general characteristics ................................................................ 28 1.1.2. The canonical miRNA biogenesis ................................................................................ 29 1.1.3 The loading RISC.......................................................................................................... 32 1.1.3.1 The loading RISC: Dicer ........................................................................................... 32 1.1.3.2 The loading RISC: TRBP ........................................................................................... 35 1.1.3.3 The loading RISC: Ago2 ............................................................................................ 37 1.1.4 MiRNA strand selection and pairing ............................................................................ 38 1.1.5 P-bodies ........................................................................................................................ 39 1.2 Human immunodeficiency virus........................................................................................ 43 1.2.1 HIV Discovery, origins, and contemporary impacts .................................................... 43 1.2.2 HIV-1 genome and virion structure .............................................................................. 46 1.2.3 The HIV-1 replication cycle and Gag protein .............................................................. 49 1.2.3.1 Virus binding, entry, and the reverse transcription................................................... 51 1.2.3.2 Integration and transcription .................................................................................... 52 1.2.3.3 Gag, viral assembly, release and maturation. ........................................................... 54 1.2.4 HIV-1 infection ............................................................................................................. 57 1.2.4.1 Acute infection and the founder virus. ....................................................................... 59 1.2.4.2 Chronic infection and AIDS. ..................................................................................... 60 1.2.5 Current ART ................................................................................................................. 61 1 1.2.6 Latency and viral reservoir .......................................................................................... 62 1.2.7 HIV-1 cure strategies.................................................................................................... 63 1.3 Zika virus ............................................................................................................................ 66 1.3.1 Emergence of Zika virus ............................................................................................... 66 1.3.2 ZIKV and genome ......................................................................................................... 68 1.3.3 ZIKV replication cycle .................................................................................................. 71 1.3.3.1 Binding, entry, fusion and release ............................................................................. 71 1.3.3.2 Translation, polyprotein cleavage and RNA replication ........................................... 71 1.3.3.3 Assembly and release................................................................................................. 72 1.3.4. ZIKV phylogenomics and pathogenesis ....................................................................... 75 1.3.5. ZIKV transmission ....................................................................................................... 76 1.3.6 ZIKV pathology............................................................................................................. 78 1.3.6.1 CZVS, neurologic abnormalities ............................................................................... 79 1.3.6.2 CZVS, ocular and other abnormalities ...................................................................... 79 1.3.7. ZIKV, potential treatments and vaccines .................................................................... 80 1.4. RNAi and viruses interplay, HIV-1 and ZIKV ................................................................ 82 1.4.1 miRNAs and HIV-1 ....................................................................................................... 83 1.4.1.1 Encoded vmiRNAs by HIV-1...................................................................................... 83 1.4.1.2 miRNAs that directly target HIV-1 RNA.................................................................... 84 1.4.1.3 miRNAs that impair HIV-1 through host dependency factors ................................... 85 1.4.1.4 miRNAs that promote HIV-1 replication ................................................................... 86 1.4.2 RNAi proteins and HIV-1 ............................................................................................. 87 1.4.3 miRNAs and ZIKV ........................................................................................................ 91 1.5 REFERENCES .................................................................................................................. 93 1.6 Rationale and hypothesis ................................................................................................. 122 1.6.1 Objectives ....................................................................................................................... 122 1.6.2 References ................................................................................................................... 124 CHAPTER II ............................................................................................................................... 125 HIV-1 Gag interacts with Dicer and increases its binding to specific microRNAs. ........ 125 2.1 PREFACE ........................................................................................................................ 126 2.2 ABSTRACT ..................................................................................................................... 128 2.3 INTRODUCTION ........................................................................................................... 129 2 2.4 RESULTS ......................................................................................................................... 132 2.4.1 RNA interference remains functional in cells expressing HIV-1 ................................ 132 2.4.2 HIV-1 expression in human cells does not change the localization of RISC proteins in the cytoplasm ....................................................................................................................... 134 2.4.3 Viral Gag colocalizes with Dicer in HIV-1 producing cells ...................................... 136 2.4.4 Dicer and HIV-1 Gag interaction is independent of RNA .......................................... 138 2.4.5 Dicer and Gag are in close proximity in both the nucleus and cytoplasm ................. 139 2.4.6 Dicer catalytic activity on pre-miRNA Let7c and pre-miRNA29a is maintained in the presence of Gag ................................................................................................................... 141 2.4.7 Dicer/Gag interaction results in higher binding of specific miRNAs. ........................ 142 2.4.8 Increased binding of miR642a 3p, miR766 5p and miR766 3p to Dicer when HIV-1 Gag is co-expressed. ............................................................................................................ 145 2.4.9 HIV-1 interacting
Load more

Recommended publications
  • Deregulated Mirnas in Bone Health Epigenetic Roles in Osteoporosis
    Bone 122 (2019) 52–75 Contents lists available at ScienceDirect Bone journal homepage: www.elsevier.com/locate/bone Review Article Deregulated miRNAs in bone health: Epigenetic roles in osteoporosis T ⁎ D. Bellaviaa, , A. De Lucaa, V. Carinaa, V. Costaa, L. Raimondia, F. Salamannab, R. Alessandroc,d, M. Finib, G. Giavaresib a IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy b IRCCS Istituto Ortopedico Rizzoli, Laboratory of Preclinical and Surgical Studies, Bologna, Italy c Department of Biopathology and Medical Biotechnologies, Section of Biology and Genetics, University of Palermo, Palermo 90133, Italy d Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Italy. ARTICLE INFO ABSTRACT Keywords: MicroRNA (miRNA) has shown to enhance or inhibit cell proliferation, differentiation and activity of different miRNA cell types in bone tissue. The discovery of miRNA actions and their targets has helped to identify them as novel Osteoporosis regulations actors in bone. Various studies have shown that miRNA deregulation mediates the progression of Osteogenesis bone-related pathologies, such as osteoporosis. Osteoblast The present review intends to give an exhaustive overview of miRNAs with experimentally validated targets Osteoclast involved in bone homeostasis and highlight their possible role in osteoporosis development. Moreover, the review analyzes miRNAs identified in clinical trials and involved in osteoporosis. 1. Introduction degradation [7]. Mature miRNAs are generated by the sequential cleavage of precursor transcripts, indicated as pri-miRNAs, that is Bone is a mineralized connective tissue that has two essential bio- cleaved in the nucleus by Drosha and the Di George syndrome critical logical roles: 1) a mechanical role – supporting body locomotion and region gene 8 (DGCR8) complex, producing a hairpin of 70–100 nu- protecting brain and splanchnic organs; and 2) a metabolic role - reg- cleotides, named pre-miRNA.
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • Functional Genomics Analysis of Vitamin D Effects on CD4+ T Cells In
    Functional genomics analysis of vitamin D effects PNAS PLUS on CD4+ T cells in vivo in experimental autoimmune encephalomyelitis Manuel Zeitelhofera,b, Milena Z. Adzemovica, David Gomez-Cabreroc,d,e, Petra Bergmana, Sonja Hochmeisterf, Marie N’diayea, Atul Paulsona, Sabrina Ruhrmanna, Malin Almgrena, Jesper N. Tegnérc,d,g, Tomas J. Ekströma, André Ortlieb Guerreiro-Cacaisa, and Maja Jagodica,1 aDepartment of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden; bVascular Biology Unit, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden; cUnit of Computational Medicine, Department of Medicine, Solna, Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden; dScience for Life Laboratory, 171 21 Solna, Sweden; eMucosal and Salivary Biology Division, King’s College London Dental Institute, London SE1 9RT, United Kingdom; fDepartment of General Neurology, Medical University of Graz, 8036 Graz, Austria; and gBiological and Environmental Sciences and Engineering Division, Computer, Electrical and Mathematical Sciences and Engineering Division, King Abdullah University of Science and Technology, 23955 Thuwal, Kingdom of Saudi Arabia Edited by Tomas G. M. Hokfelt, Karolinska Institutet, Stockholm, Sweden, and approved January 19, 2017 (received for review September 24, 2016) Vitamin D exerts multiple immunomodulatory functions and has autoimmune destruction of myelin, axonal loss, and brain atro- been implicated in the etiology and treatment of several autoim- phy (6). Increased risk of developing MS has been described in mune diseases, including multiple sclerosis (MS). We have previously carriers of rare and common variants of the CYP27B gene (7, 8), reported that in juvenile/adolescent rats, vitamin D supplementation which encodes the enzyme that catalyzes the last step in con- protects from experimental autoimmune encephalomyelitis (EAE), a verting vitamin D to its active form, from 25(OH)D3 to 1,25 model of MS.
    [Show full text]
  • Involvement of Human Micro-RNA in Growth and Response to Chemotherapy in Human Cholangiocarcinoma Cell Lines
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Texas A&M Repository GASTROENTEROLOGY 2006;130:2113–2129 Involvement of Human Micro-RNA in Growth and Response to Chemotherapy in Human Cholangiocarcinoma Cell Lines FANYIN MENG,* ROGER HENSON,* MOLLY LANG,* HANIA WEHBE,* SHAIL MAHESHWARI,* JOSHUA T. MENDELL,‡ JINMAI JIANG,§ THOMAS D. SCHMITTGEN,§ and TUSHAR PATEL* *Department of Internal Medicine, Scott and White Clinic, Texas A&M University System Health Science Center College of Medicine, Temple, Texas; ‡The Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and §College of Pharmacy, The Ohio State University, Columbus, Ohio Background & Aims: Micro-RNA (miRNA) are endoge- age of target mRNA. Although several hundred miRNA nous regulatory RNA molecules that modulate gene have been cloned or predicted, a functional role for these expression. Alterations in miRNA expression can contrib- in many cellular processes has not been fully elucidated.1 ute to tumor growth by modulating the functional ex- The best characterized role of miRNA has been as a pression of critical genes involved in tumor cell prolifer- developmental regulator in Caenorhabditis elegans and ation or survival. Our aims were to identify specific Drosophilia. More recently, several other roles have been miRNA involved in the regulation of cholangiocarcinoma described including regulation of apoptosis and differen- growth and response to chemotherapy. Methods: miRNA tiation. miRNA are expressed as long precursor RNA expression in malignant and nonmalignant human that are processed by a single nuclease Drosha prior to cholangiocytes was assessed using a microarray. Ex- pression of selected miRNA and their precursors was transport into the cytoplasm by an exportin-5-dependent evaluated by Northern blots and real-time polymerase mechanism.
    [Show full text]
  • Epigenetic of Colorectal Cancer: a Focus on Micrornas
    André Filipe Afonso de Sousa Fonseca Epigenetic of colorectal cancer: a focus on microRNAs UNIVERSIDADE DO ALGARVE Departamento de Ciências Biomédicas e Medicina 2018 André Filipe Afonso de Sousa Fonseca Epigenetic of colorectal cancer: a focus on microRNAs Master in Oncobiology - Molecular Mechanisms of Cancer This work was done under the supervision of: Pedro Castelo-Branco, Ph.D Vânia Palma Roberto, Ph.D UNIVERSIDADE DO ALGARVE Departamento de Ciências Biomédicas e Medicina 2018 i ii Epigenetic of colorectal cancer: a focus on microRNAs Declaração de autoria do trabalho Declaro ser a autora deste trabalho, que é original e inédito. Autores e trabalhos consultados estão devidamente citados no texto e constam da listagem de referências incluída. “I declare that I am the author of this work, that is original and unpublished. Authors and works consulted are properly cited in the text and included in the list of references.” ______________________________________ (André Fonseca) iii Copyright © 2018 André Filipe Afonso de Sousa Fonseca A Universidade do Algarve reserva para si o direito, em conformidade com o disposto no Código do Direito de Autor e dos Direitos Conexos, de arquivar, reproduzir e publicar a obra, independentemente do meio utilizado, bem como de a divulgar através de repositórios científicos e de admitir a sua cópia e distribuição para fins meramente educacionais ou de investigação e não comerciais, conquanto seja dado o devido crédito ao autor e editor respetivos. iv “If you want to succeed as bad as you want to breathe then you will be successful!” - Eric Thomas v vi Agradecimentos Em primeiro lugar gostaria de agradecer ao meu orientador, o professor doutor Pedro Castelo-Branco por me ter acolhido no seu laboratório, por depositar em mim a sua confiança e acreditar na minha capacidade para realizar o seguinte trabalho.
    [Show full text]
  • Epigenetic Alterations and Advancement of Treatment in Peripheral T-Cell Lymphoma
    Zhang and Zhang Clin Epigenet (2020) 12:169 https://doi.org/10.1186/s13148-020-00962-x REVIEW Open Access Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma Ping Zhang1,2 and Mingzhi Zhang1,2* Abstract Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of clinically aggressive diseases associated with poor prognosis. Except for ALK anaplastic large-cell lymphoma (ALCL), most peripheral T-cell lymphomas are highly malignant and have an aggressive+ disease course and poor clinical outcomes, with a poor remission rate and frequent relapse after frst-line treatment. Aberrant epigenetic alterations play an important role in the pathogenesis and development of specifc types of peripheral T-cell lymphoma, including the regulation of the expression of genes and signal transduction. The most common epigenetic alterations are DNA methylation and histone modifcation. Histone modifcation alters the level of gene expression by regulating the acetylation status of lysine residues on the promoter surrounding histones, often leading to the silencing of tumour suppressor genes or the overexpression of proto-oncogenes in lymphoma. DNA methylation refers to CpG islands, generally leading to tumour suppressor gene transcriptional silencing. Genetic studies have also shown that some recurrent mutations in genes involved in the epi- genetic machinery, including TET2, IDH2-R172, DNMT3A, RHOA, CD28, IDH2, TET2, MLL2, KMT2A, KDM6A, CREBBP, and EP300, have been observed in cases of PTCL. The aberrant expression of miRNAs has also gradually become a diag- nostic biomarker. These provide a reasonable molecular mechanism for epigenetic modifying drugs in the treatment of PTCL. As epigenetic drugs implicated in lymphoma have been continually reported in recent years, many new ideas for the diagnosis, treatment, and prognosis of PTCL originate from epigenetics in recent years.
    [Show full text]
  • Download Special Issue
    International Journal of Genomics Noncoding RNAs in Health and Disease Lead Guest Editor: Michele Purrello Guest Editors: Massimo Romani and Davide Barbagallo Noncoding RNAs in Health and Disease International Journal of Genomics Noncoding RNAs in Health and Disease Lead Guest Editor: Michele Purrello Guest Editors: Massimo Romani and Davide Barbagallo Copyright © 2018 Hindawi. All rights reserved. This is a special issue published in “International Journal of Genomics.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board Andrea C. Belin, Sweden M. Hadzopoulou-Cladaras, Greece Ferenc Olasz, Hungary Jacques Camonis, France Sylvia Hagemann, Austria Elena Pasyukova, Russia Prabhakara V. Choudary, USA Henry Heng, USA Graziano Pesole, Italy Martine A. Collart, Switzerland Eivind Hovig, Norway Giulia Piaggio, Italy Monika Dmitrzak-Weglarz, Poland Hieronim Jakubowski, USA Mohamed Salem, USA Marco Gerdol, Italy B.-H. Jeong, Republic of Korea Wilfred van IJcken, Netherlands João Paulo Gomes, Portugal Atsushi Kurabayashi, Japan Brian Wigdahl, USA Soraya E. Gutierrez, Chile Giuliana Napolitano, Italy Jinfa Zhang, USA Contents Noncoding RNAs in Health and Disease Davide Barbagallo, Gaetano Vittone, Massimo Romani , and Michele Purrello Volume 2018, Article ID 9135073, 2 pages Circular RNAs: Biogenesis, Function, and a Role as Possible Cancer Biomarkers Luka Bolha,
    [Show full text]
  • Eting Disabled Homolog-2
    Oncogene (2012) 31, 764–775 & 2012 Macmillan Publishers Limited All rights reserved 0950-9232/12 www.nature.com/onc ORIGINAL ARTICLE Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2 A Chao1,7, C-Y Lin1,7, Y-S Lee2,3, C-L Tsai1, P-C Wei1,4, S Hsueh5, T-I Wu1, C-N Tsai6, C-J Wang1, A-S Chao1, T-H Wang1,2,4 and C-H Lai1 1Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Tao-Yuan, Taiwan; 2Genomic Medicine Research Core Laboratory, Chang Gung Memorial Hospital, Gwei-Shan, Taiwan; 3Department of Biotechnology, Ming-Chuan University, Tao-Yuan, Taiwan; 4Graduate Institute of Biomedical Sciences, Chang Gung University, Gwei-Shan, Taiwan; 5Department of Clinical Pathology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Tao-Yuan, Taiwan and 6Graduate Institute of Clinical Medical Sciences, Chang Gung University, Gwei-Shan, Taiwan MicroRNAs (miRNAs) play important roles in tumorigen- Keywords: microRNA; miR-187; Dab2; epithelial– esis by regulating oncogenes and tumor-suppressor genes. In mesenchymal transition (EMT) this study, miR-187 and miR-200a were found to be expressed at higher levels in ovarian cancers than in benign tumors. In patients with ovarian cancer, however, higher levels of miR-187 and miR-200a expression were para- Introduction doxically associated with better OS and recurrence-free survival. Further, multivariate analysis showed that miR- Epithelial ovarian cancer is one of the deadliest 187 served as an independent prognostic factor for patients malignancies in women (Jemal et al., 2007).
    [Show full text]
  • Combining Feature Selection and Shape Analysis Uncovers Precise
    Combining feature selection and shape analysis uncovers precise rules for miRNA regulation in Huntington’s disease mice Lucile Mégret, Satish Sasidharan Nair, Julia Dancourt, Jeff Aaronson, Jim Rosinski, Christian Neri To cite this version: Lucile Mégret, Satish Sasidharan Nair, Julia Dancourt, Jeff Aaronson, Jim Rosinski, et al.. Combining feature selection and shape analysis uncovers precise rules for miRNA regulation in Huntington’s disease mice. BMC Bioinformatics, BioMed Central, 2020, 21 (1), pp.75. 10.1186/s12859-020-3418- 9. inserm-02512089 HAL Id: inserm-02512089 https://www.hal.inserm.fr/inserm-02512089 Submitted on 19 Mar 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Mégret et al. BMC Bioinformatics (2020) 21:75 https://doi.org/10.1186/s12859-020-3418-9 RESEARCH ARTICLE Open Access Combining feature selection and shape analysis uncovers precise rules for miRNA regulation in Huntington’s disease mice Lucile Mégret1*, Satish Sasidharan Nair1, Julia Dancourt1, Jeff Aaronson2, Jim Rosinski2 and Christian Neri1* Abstract Background: MicroRNA (miRNA) regulation is associated with several diseases, including neurodegenerative diseases. Several approaches can be used for modeling miRNA regulation. However, their precision may be limited for analyzing multidimensional data.
    [Show full text]
  • COMPUTATIONAL PREDICTION of Microrna PRECURSORS and Microrna
    COMPUTATIONAL PREDICTION OF MicroRNA PRECURSORS AND MicroRNA TARGETS by BRAM SEBASTIAN (Under the Direction of Samuel E. Aggrey) ABSTRACT MicroRNA is small 22 nucleotides long non-coding RNA which regulates genes by targeting mRNA especially the 3’ UTR region. Identification of miRNAs and their targets by laboratory experiment has had limited success especially for lowly expressed therefore computational prediction approaches are needed. In this study grouping technique for miRNA precursor prediction is introduced. Compared with global alignment, grouping miRNA by classes yield a better sensitivity with very high specificity for pre-miRNA prediction even when a simple positional based secondary and primary structure alignment are used. The program TarSpec was developed to predict miR-1a and miR-124 targets based on common features of miRNA and target binding characteristics observed from alignment between miRNA and the 3’UTR targets. TarSpec obtained 78% and 77% sensitivity for miR-1a and Mir-124 targets, and 98% specificity for both. TarSpec was used to scan the Platypus 3’UTR regions. This approach predicted 734 novel potential target of miR-1a in Platypus 3’UTR regions where 98 of them are in the well annotated chromosomal region and 124 novel potential target of miR-124 where 32 of them are in the well annotated chromosomal region. Some miRNAs are derivations of transposable elements (TE). In human these TE derived miRNAs have a potential to regulate thousands of human genes. Therefore TEs as potential miRNA targets were investigated using an L2 derived miRNA miR-28. Three different miRNA target prediction programs miTarget, miRanda, and RNAhybrid were used to predict a potential miRNA-28 targets in human L2 transposable elements.
    [Show full text]
  • Genomics of Microrna
    Review TRENDS in Genetics Vol.22 No.3 March 2006 Genomics of microRNA V. Narry Kim1 and Jin-Wu Nam2 1Department of Biological Sciences and Research Center for Functional Cellulomics, Seoul National University, Seoul, 151-742, Korea 2Graduate Program in Bioinformatics, Seoul National University, Seoul, 151-742, Korea Discovered just over a decade ago, microRNA (miRNA) is approaches have been used to identify miRNA genes. now recognized as one of the major regulatory gene The first approach is through forward genetics, as is the families in eukaryotic cells. Hundreds of miRNAs have case for the first two miRNAs. In Drosophila, the gene been found in animals, plants and viruses, and there are responsible for the bantam phenotype displaying smaller certainly more to come. Through specific base-pairing body size turned out to be a miRNA gene [27]. Also in C. with mRNAs, these tiny w22-nt RNAs induce mRNA elegans, lsy-6 mutants with defects in neuronal left–right degradation or translational repression, or both. asymmetry had mutations in an miRNA gene [7]. Because Because a miRNA can target numerous mRNAs, often genetic studies are based on clear phenotypes, the in vivo in combination with other miRNAs, miRNAs operate functions of genetically identified RNAs are highly complex regulatory networks. In this article, we well established. summarize the current status of miRNA gene mining A breakthrough in large-scale miRNA identification and miRNA expression profiling. We also review up-to- was made when directional cloning was used to construct date knowledge of miRNA gene structure and the a cDNA library for endogenous small RNAs [28,29].
    [Show full text]
  • Estimating Gene Regulatory Activity Using Mathematical Optimization
    Estimating Gene Regulatory Activity using Mathematical Optimization DISSERTATION zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) im Fach Informatik eingereicht an der Mathematisch-Naturwissenschaftlichen Fakultät der Humboldt-Universität zu Berlin von M.Sc. Saskia Trescher Präsidentin der Humboldt-Universität zu Berlin: Prof. Dr.-Ing. Dr. Sabine Kunst Dekan der Mathematisch-Naturwissenschaftlichen Fakultät: Prof. Dr. Elmar Kulke Gutachter*innen: 1. Prof. Dr.-Ing. Ulf Leser, Humboldt-Universität zu Berlin 2. Prof. Dr. Katja Nowick, Freie Universität Berlin 3. Prof. Dr. Heike Siebert, Freie Universität Berlin Tag der mündlichen Prüfung: 30.04.2020 Abstract Gene regulation is one of the most important cellular processes, indispensable for the adaptability of organisms and closely interlinked with several classes of pathogenesis and their progression, including cancer. The elucidation of regulatory mechanisms can be approached by a multitude of experimental methods, yet integration of the resulting het- erogeneous, large, and noisy data sets into comprehensive and tissue or disease-specific cellular models requires rigorous computational methods. Over the last decade, numer- ous methods have been proposed trying to infer actual regulatory events in a sample. A prominent class of methods models genome-wide gene expression as sets of (linear) equations over the activity and relationships of transcription factors (TFs), genes and other factors and optimizes parameters to fit the measured expression intensities. In various settings, these methods produced promising results in terms of estimating TF activity and identifying key biomarkers for specific phenotypes. However, despite their common root in mathematical optimization, they vastly differ in the types of experi- mental data being integrated, the background knowledge necessary for their application, the granularity of their regulatory model, the concrete paradigm used for solving the optimization problem and the data sets used for evaluation.
    [Show full text]